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Abstract Mass spectrometry (MS) techniques, because
of their sensitivity and selectivity, have become methods of
choice to characterize the human metabolome and MS-
based metabolomics is increasingly used to characterize the
complex metabolic effects of nutrients or foods. However
progress is still hampered by many unsolved problems and
most notably the lack of well established and standardized
methods or procedures, and the difﬁculties still met in the
identiﬁcation of the metabolites inﬂuenced by a given
nutritional intervention. The purpose of this paper is to
review the main obstacles limiting progress and to make
recommendations to overcome them. Propositions are
made to improve the mode of collection and preparation of
biological samples, the coverage and quality of mass
spectrometry analyses, the extraction and exploitation of
the raw data, the identiﬁcation of the metabolites and the
biological interpretation of the results.
Keywords Metabolomics  Mass spectrometry 
Nutrition  Method development
1 Introduction
Nutrition research in the 20th century led to the discovery
of the functions of essential nutrients. Nutritional recom-
mendations have been made for populations to cover the
needs of these essential nutrients, and to ensure the good
functioning of the organism. Beyond these essential
effects, it is also clear today that many of these nutrients,
together with non-essential bioactive compounds also
present in foods and the diet, interact with a number of
metabolic pathways and inﬂuence health, reducing or
increasing the risk of diseases such as cancers or cardio-
vascular diseases. Deciphering these complex interactions
between nutrients and the human organism constitutes a
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DOI 10.1007/s11306-009-0168-0considerable challenge for the 21st century (Doets et al.
2008).
The classical approaches in nutrition research are
hypothesis-driven. Methods used to prove or disprove a
hypothesis were largely derived from those used in phar-
macology. However nutrients do not speciﬁcally interact
with a deﬁned target like some drugs but they most likely
interact with a number of targets, metabolic pathways and
functions.Furthermorethemagnitudeoftheireffectsisoften
much lower than that commonly observed for drugs. Recent
research on vitamin E illustrates the limits of these approa-
ches: tocopherols do not only have a vitamin function but
theyarealsopowerfulfreeradicalscavengers.Addedtofats,
theylimittheirperoxidationandincrease theirshelflife.Itis
knownfromanimal studiesandshort-termclinicaltrialsthat
they can also limit LDL peroxidation in the artery wall and
improve some surrogate markers of cardiovascular disease
risk (Huang et al. 2002; Meydani 2004). However, despite
such evidence, the results of large intervention studies were
largelydisappointinganddidnotshowareductionofdisease
and mortality outcome (Bjelakovic et al. 2007; Miller et al.
2004).Therefore,short-terminterventionstudiesandtheuse
of current surrogate markers failed to predict the effects of
vitamin E supplementation on diseases and mortality.
Omics approaches and metabolomics in particular should
allow tocharacterize the effects ofa nutrient, a foodoradiet
with much more precision. Metabolomics allows to analyse
hundreds of metabolites in a given biological sample (bio-
ﬂuid, tissue, cells, etc.). When applied to urine or plasma
samples, it allows to differentiate individual phenotypes
betterthanwithconventionalclinicalendpointsorwithsmall
sets of metabolites (Assfalg et al. 2008; Brindle et al. 2002;
Yang et al. 2004). It also allows to explore the metabolic
effects of a nutrient in a more global way. In the ﬁeld of
nutrition, metabolomics has been used to characterize the
effects of botha deﬁciency or asupplementation ofdifferent
nutrients, and to compare the metabolic effects of closely
related foods such as whole-grain or reﬁned wheat ﬂours
(Fardet et al. 2007; Rezzi et al. 2007). It may also allow to
better separate the effects of the diet from those of con-
founding factors such as age, gender, physiological states
and lifestyle once the effects of these factors on the metab-
olome will have been characterized in sufﬁcient details.
Metabolomics and the food metabolome made of all the
products of food digestion may also be used to estimate the
food or nutrient intake from a urine, sera or plasma sample
(Fardetetal.2008b;Wishart2008).Metabolomicsmayhelp
solving problems associated to the methods currently used
for measuring food intake (Manach et al. 2009). A literature
search retrieved 128 papers dealing with metabolomics in
human nutrition and published since 2001 (Web of Science,
December 22, 2008). They included 45 original papers, 60
reviews and 23 papers focused on method development or
the characterization of metabolome variability. Nearly two-
third of these papers were published in the last 2 years.
Inthemajorityoforiginalpapers(62%),protonNMRwas
used for data acquisition. However, due to its more limited
sensitivity, not more than 60 different metabolites are com-
monly estimated in biological samples (Martin et al. 2007).
HPLC-separations coupledwithcoulometricelectrodearray
detectorsareextremelysensitive(detectionofsubnanomolar
electrochemically active species in sera), and can detect
[1000 compounds in sera (Milbury 1997; Vigneau-Calla-
han et al. 2001), but their use remains limited by low
throughput, inability to observe non-electrochemically
active species and difﬁculties associated with metabolite
identiﬁcation. Mass spectrometry (MS) techniques are also
highly sensitive and provide spectral information (exact
mass of molecular ion, fragmentation patterns) which con-
tribute to the identiﬁcation of the metabolites (Dettmer et al.
2007). For these reasons, the number of MS-based meta-
bolomics studies grows quickly and now exceeds that of
NMR-based studies (Dettmer et al. 2007). Both targeted
proﬁling (in which metabolites are known a priori) and ﬁn-
gerprinting (the identity of the metabolites of interest is
established a posteriori) have been carried out in MS-based
metabolomics. Targeted proﬁling is usually developed for
quantiﬁcation of a given class of metabolites (lipids, fatty
acids, acylcarnitines, bile acids, organic acids, nucleosides,
etc.). It has been used for many years in nutrition research.
However the increasing power of MS techniques which
allows today the simultaneous analysis of several hundred
metabolites explains why it has been called metabolomics
(Altmaier et al. 2008; Watkins et al. 2002). MS-based ﬁn-
gerprinting was only applied recently to nutritionwith about
10 papers published in 2008 (Clish et al. 2004; Fardet et al.
2008a; Kuhl et al. 2008; Shen et al. 2008). This approach
offers a considerable potential but progress is still hampered
by many unsolved problems (Table 1) and most notably the
lack of well established and standardized methods or pro-
cedures, and the difﬁculties still met in the identiﬁcation of
thediscriminatingmetabolites(Jiyeetal.2005;Lawtonetal.
2008; Wishart et al. 2008).
This paper is based on the discussions held during the
workshop ‘‘Tools and Methods for Mass Spectrometry
Metabolomics in Nutrition’’ organized by NuGO, the
European Nutrigenomics Organization (www.nugo.org)o n
December 12–14, 2007 in Clermont-Ferrand (France).
Each section of the manuscript summarizes the problems
identiﬁed and proposes recommendations to solve them.
2 Sampling strategy for metabolomics
In metabolomic studies, minimisation of unwanted sources
of variation is important. Such variation can be broadly
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123Table 1 Problems and recommendations for further developing MS-based metabolomics in nutrition research
Problems Solutions/recommendations
Study protocol not optimized for
metabolomics
Control the diet wherever possible
Control the time of sampling
Explore the inﬂuence of the diet or nutrient in perturbed conditions (challenge tests) to better reveal
low magnitude effects often characterizing nutritional interventions
Interindividual variations larger than
treatment effects
Cross-over design preferred to parallel design for nutritional interventions
At least two sampling points per person, before and after intervention
Time–course metabolomics
Unwanted sources of variations
associated to sample collection and
storage
For serum collection, control the clotting conditions
For plasma, standardize deproteinization methods
Ensure proper sample preservation (preservatives and low temperature)
Insufﬁcient coverage of MS proﬁling
methods
Select and develop a limited set of analytical methods allowing to cover the highest fraction of the
known human metabolome
Increase the capacity of chromatographic systems
Develop bidimensional separation techniques
Limited quality of MS analyses Limit ion suppression effects in LC–MS (increase chromatographic resolution, use nanospray
ionization)
Develop isotope tagging methods for targeted metabolite classes
Establish gold standards of deﬁned metabolite synthetic mixtures representative of bioﬂuids to assess
and validate method performance
Analytical data not easily compared
between studies or laboratories
Ensure proper validation of the analytical methods
Generalize the use of quality control samples
Generalize the use of a set of spiked markers of retention time
Develop metabolite quantiﬁcation rather than semi-quantiﬁcation
Inconsistent results of data extraction Compare performance of various data extraction tools
Improved tools to be developed with notably interactive review and error correction functionalities
and generic tools applicable to data sets originating from various MS instruments
Insufﬁcient exploitation of the data and
data overﬁtting
Develop the informatics plan together with the study design once the question(s) of interest has been
carefully deﬁned
Fully disclose the methods used and encourage standardization for reporting data
Incomplete metabolite identiﬁcation in
metabolomics ﬁngerprints
Metabolite identiﬁcation should be made a priority in metabolomics studies
Further develop MS-based metabolite databases (including food components/additives and their
metabolites formed in the body)
Further develop MS-based metabolite identiﬁcation softwares
Develop elemental or chemical formula prediction softwares
Encourage the development of publicly accessible databases and common repository of MS reference
compound spectra
Difﬁcult interpretation of changes in
metabolomics ﬁngerprints
Build a knowledge base on the biological meaning of changes of metabolite concentrations in body
ﬂuids and develop metabo-ontologies
Further clarify the links between changes in metabolite concentrations in body ﬂuids with organ
physiology/pathology using animal models
Deﬁne ‘‘normal’’ concentrations as compared to concentrations characterizing early disease onsets
and diseases
Further understand the biochemical relationships between metabolic pathways and network biology
Improve match between MS analytical performance and metabolism areas of major biological
interest
Develop ‘‘wish lists’’ of metabolites of interest and promote the development of metabolomics
platforms to quantify the corresponding metabolites
Develop metabolite annotation to differentiate endogenous, exogenous and microbial metabolites
Promote standardization of methods and data formats as well as data warehousing to allow multi-
study comparison
Develop an integrated workbench with all data analysis tools
Develop a common depository of all available tools, knowledge and results
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123summarised as analytical and biological variation and
examples include (Maheret al. 2007):(1) samplecollection,
storage and stability, (2) sample pre-treatment, including
metabolite extraction, prior to analysis, (3) instrument
variation/stability, (4) intra-individual variations due to
environmental factors such as diurnal variation and stress,
(5) inter-individual variations due to genetic factors, (6)
inter-individual variations due to the presence/absence of
disease. Failure to minimise such unwanted variation can
have a negative impact on the outcome of the study
resulting in, for example, identiﬁcation of fewer biomark-
ers. This section of the workshop addressed some of the
points above in the context of designing metabolomic
studies for nutritional studies. Most metabolomic studies
are designed to address a speciﬁc hypothesis and while a lot
of attention is devoted to the design from the hypothesis
view point it is easy to overlook sample collection, stability
and storage issues. Recently, there have been a number of
studies highlighting the importance of these points (Gika
et al. 2007, 2008; Lauridsen et al. 2007; Maher et al. 2007;
Saude et al. 2007; Saude and Sykes 2007; Shurubor et al.
2007; Teahan et al. 2006; Zhang et al. 2007). While a
number of these studies have been carried out using NMR
spectroscopy, the same issues and recommendations will
also apply to LC–MS and GC–MS approaches.
When considering the design of a metabolomic study the
ﬁrst issue to consider is the time of the sampling. Diurnal
variation has been documented in urine samples taken from
healthy volunteers (Maher et al. 2007; Walsh et al. 2006).
However, one cannot simply decide to collect fasting
morning samples as changes have been reported between
samples collected with a 2 h separation (Maher et al.
2007). To minimise variation a very speciﬁc description of
the collection of urine sample needs to be given such as
‘‘ﬁrst void midstream urine samples’’.
The next issue to be addressed is the effects of preser-
vatives on metabolic urinary proﬁles. Lauridsen et al.
investigated the effects of addition of NaN3 and NaF to
human urine samples (Lauridsen et al. 2007). The authors
concluded that for long-term storage at -25 and -80 C
there was no requirement for the preservative. However, if
preservative has to be added, for example due to extended
storage at room temperature, the recommended pre-
servative is NaN3 because of limited interferences with
NMR spectra. It was shown to slow down changes of the
metabolite concentrations in urine kept at room tempera-
ture (Saude and Sykes 2007).
With respect to blood sample collection recent studies
have also highlighted the importance of how collection is
performed. The generic advice of collection of fasting blood
samples is not enough if systematic bias is to be avoided. In
fact, details such as clotting time, clotting temperature and
treatment conditions prior to centrifugation need to be
considered. Teahan et al. demonstrated that clotting time
had an impact on the metabolic proﬁle and that clotting on
ice delayed the observed changes (Teahan et al. 2006).
When collecting serum samples for metabolomics studies
one must record the clotting time and temperature at which
the clotting occurred and standardise across all samples.
Another issue which is often overlooked is that blood col-
lection tubes can release materials into the samples and
interfere with the mass spectrometry analysis (Drake et al.
2004). In addition, batch differences have been reported for
certain vacutainers and again these concerns should be
addressed in study design. With respect to plasma samples
one must consider the anticoagulant to be used and possi-
bility of unwanted peaks.
Sample storage and stability for human bioﬂuids with
respect to metabolomics are issues that have been addres-
sed for NMR based and LC–MS based approaches. Lau-
ridsen et al. showed that urine samples should be stored at
or below -25 C and recommended not to store at 4 C for
prolonged periods (Lauridsen et al. 2007). No beneﬁcial
effect of storing at lower temperature was seen for the
duration of this study (up to 26 weeks) using NMR based
metabolomics. Similar results were reported by Maher
et al. using NMR based metabolomics (Maher et al. 2007).
A recent study by Gika et al. showed using untargeted LC–
MS and UPLC–MS approaches that human urine samples
were stable for up to 6 months stored at -20 and -80 C
(Gika et al. 2008). Short term storage of human urine
samples at 4 C was shown to be stable for up to at least
48 h using LC–MS proﬁling meaning that samples for this
type of work can be considered stable in a chilled auto-
sampler (Gika et al. 2008).
The effects of freeze thaw cycles on the metabolic
proﬁles have been investigated using NMR, LC–MS and
GC–MS. In the case of the LC–MS study, freeze thaw
cycles of up to 9 cycles of human urine samples, taken
from 6 individuals, did not impact on the clustering of the
data in a PCA plot (Gika et al. 2007, 2008). Investigating
the effects of the a freeze thaw cycle on the relative con-
centrations of 26 compounds in rat urine using GC–MS
Zhang et al. showed that one freeze thaw cycle did not
result in signiﬁcant differences for the compounds analysed
(Zhang et al. 2007). Studies in our laboratory showed that
one freeze thaw cycle had minimal impact on the NMR
spectra and the within bin correlation was above 0.97 for
90% of the regions studied (unpublished data). Saude and
Sykes used a targeted NMR based approach and reported
that repeated freeze thaw cycles over 4 weeks resulted in
an intermediate degree of metabolite change when com-
pared to storage at room temperature and at -80 C (Saude
and Sykes 2007). Overall, to minimise confounding factors
in urinary metabolomics it is recommended to keep freeze-
thaw cycles to a minimum.
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123Other unwanted sources of variation that are important
to consider in study design are recent consumption of
certain foods and medication. Recently, it has been dem-
onstrated that standardisation of the subjects diet reduced
the variation in the urinary metabolic proﬁles (Walsh et al.
2006). In addition, there are many reports where diet,
alcohol and medication have resulted in outlying samples.
When setting out to design metabolomics studies it is
essential that one considers food restrictions and medica-
tion and that subjects record their dietary and medication
intake 24 h prior to bioﬂuid collection and avoid the use of
medication. A well planned study with collection of suf-
ﬁcient metadata (dietary, medication and physical activity
at a minimum) should allow one to avoid the need for a
pilot study and to use metabolomics to its full potential.
Blood samples contain a range of low molecular weight
compounds and proteins and efﬁcient removal of the pro-
teins is necessary prior to LC–MS or GC–MS analysis for
metabolomic studies. Since human blood contains a range
of low molecular weight compounds with a wide range of
concentrations, stability and ability to bind to proteins the
development of an extraction procedure is complex.
Recently, Want et al. examined a range of deproteinization
methods in combination with LC–MS proﬁling and found
that methanol precipitation was the most effective and
reproducible approach resulting in the detection of over
2000 metabolite features and less than 2% protein (Want
et al. 2006). A recent study investigated two protein pre-
cipitation methods for plasma samples and found the
methanol method to be superior comparing the number of
signals, sensitivity and reproducibility for use with UPLC–
MS (Bruce et al. 2007). In addition, for use with GC–MS
the methanol extraction procedure was found to be highly
efﬁcient and reproducible (Jiye et al. 2005). However, it is
necessary to point out that these studies have used an un-
targeted proﬁling approach and in the case of targeted
approaches the deproteinization protocol to be used will
vary according to the metabolite classes targeted. While
protein depletion is not necessary prior to acquisition of
NMR spectra previous studies have shown that it can be
useful for gaining information on low-concentration
metabolites (Daykin et al. 2002; Tiziani et al. 2008).
Faecal samples are an example of another bioﬂuid rel-
evant to nutritional research which requires pre-treatment
prior to metabolomic analysis. Recent papers have
appeared in the literature using both water extraction and
methanol extraction procedures of frozen faecal samples in
conjunction with NMR based proﬁling (Jacobs et al. 2008;
Saric et al. 2008). Both methods gave reproducible proﬁles
which contained complementary information (Jacobs et al.
2008). In addition, Saric et al. investigated the differences
between water extractions from fresh and frozen stool
samples and only found higher concentrations of amino
acids and glucose in frozen samples. As a result they
concluded that use of frozen samples was acceptable (Saric
et al. 2008).
All of the issues described above need to be considered
and standard operating procedures (SOPs) drawn up for the
bioﬂuids used for each metabolomic study. The importance
of this cannot be underestimated, especially in the case of
multi-centre nutritional intervention studies, if meaningful
results are to be obtained. In addition, the adaptation of a
standard reporting system is essential for the description of
the collection of bioﬂuids relevant to nutritional research.
To this end steps have been taken by the metabolomics
standards initiative and a recent publication describes the
recommended reporting requirements for biological sam-
ples (Grifﬁn et al. 2007). In addition, NuGO intends to
compile SOPs relevant to sample collection, storage and
collection for nutritional metabolomics studies.
3 Mass spectrometry for metabolomics
Mass spectrometry (MS) has played an important role in
the development of methods for proﬁling of metabolites
due to its selectivity and sensitivity. Broad screening
approaches of metabolites in bioﬂuids combined with
biostatistical tools for data evaluation have been devel-
oped, ﬁrst by GC and GC–MS in the 1970s. In the 1990s,
major improvements in interfacing LC and MS (electro-
spray and atmospheric pressure chemical ionization)
enabled the use of LC–MS for metabolite proﬁling. How-
ever, more comprehensive metabolite proﬁling methods
were only reported after 2000 (van der Greef and Smilde
2005). Actually, for the acquisition of a comprehensive
metabolite proﬁle more than one method has to be used
(van der Greef et al. 2007). As the physicochemical
properties (e.g. pKa, polarity, size) of metabolites cover a
wide range, there is not one separation method (GC, LC or
CE) to separate all metabolites with one method only. In
addition, there is not one detector that can measure all
metabolites, even a mass spectrometer cannot detect all
metabolites as some metabolites do not ionize with a cer-
tain MS method, or as their concentration are too low. The
dynamic range of most mass spectrometers is also still only
3–4 orders of magnitude, whereas the range of concentra-
tions of metabolites in biological samples is often much
larger. In addition, a speciﬁc challenge in nutritional met-
abolomics is the diversity of dietary compounds and of
their metabolites formed after ingestion. Many of these
compounds have not yet been fully described. As an
example, 869 metabolites have been detected in tomato,
including 494 not found in the main metabolite databases
and still awaiting to be characterized (Iijima et al. 2008).
With most metabolite proﬁling methods there are thus
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123many unknown metabolites detected, and for many provi-
sionally identiﬁed metabolites, standards for identiﬁcation
or quantiﬁcation are often still lacking.
To analyse the different types of metabolites found in
biological samples collected in nutrition experiments,
proper sample preparation, metabolite separation and MS
detection are needed. This implies the choice of the most
appropriate separation method (GC, LC or CE), interface
between separation method and MS, and type of MS
detector. Alternatively, no separation at all is used, and a
direct infusion approach is followed (Boernsen et al. 2005).
Important criteria for selection of a method are coverage,
selectivity, dynamic range, detection limit, accuracy, pre-
cision, and price per sample.
The advantages of using GC are high separation efﬁ-
ciency and reproducible retention times, which can be
compared between different labs via the retention index
concept using retention time markers. With GC–MS, uni-
versal electron ionization (EI) is most often used. It pro-
vides response for all metabolites and characteristic,
reproducible and standardized mass spectral ﬁngerprints.
These mass spectra allow identiﬁcation of the peak when
searching in public and commercial databases. For the
analysis of medium polar and polar metabolites with GC–
MS, metabolites are ﬁrst derivatized, mostly by oximation
and subsequent silylation (Fiehn et al. 2000). The oximation
step is to protect certain carbonyl groups, and to assure that
only two peaks in a reproducible ratio are obtained for
carbohydrates. The advantage of silylation is that a wide
range of functional groups are derivatized such as hydroxyl,
amine, amide, phosphate and thiol group. However, the
disadvantage is that the derivatized products like some
amino acids are not very stable, and can degrade during
injection and separation. Therefore, internalquality markers
are added to the sample to monitor the performance of the
system (Kanani et al. 2008; Koek et al. 2006). For GC–MS,
there are generally less options for MS detectors compared
to LC–MS. Most often, a quadrupole MS or a time-of-ﬂight
(TOF)-MS detector are used. Alternatives are triple quad-
rupole MS and ion trap MS detectors. For comprehensive
GC9GC, a fast TOF-MS is used. For the identiﬁcation of
metabolites with GC–MS, chemical ionization is often used
to reveal the molecular weight of a metabolite. To increase
the peak capacity of the GC separation method, i.e.
increasing the number of separated metabolites, compre-
hensive multi-dimensional GC9GC approaches are
increasingly used (Hagan et al. 2007; Koek et al. 2008). It
has been shown that GC9GC–MS is in principle more
robust for metabolite proﬁling than GC–MS. However, data
is more complex, and no optimal solution for data pro-
cessing is available yet (Koek et al. 2008).
For LC–MS, the advantage is that in principle no
derivatization is required for the analysis of polar or high
molecular weight metabolites, allowing fast analysis of
small samples. A wide range of different detectors are
available for LC–MS, ranging from ultra-high resolution
MS such as Fourier transform ion cyclotron resonance (FT-
ICR) or Orbitrap FT, and high resolution MS (TOF) to low
resolution MS (ion traps, triple quads) up to hybrid sys-
tems. Most recent addition are ion-mobility TOF-MS sys-
tems (Dwivedi et al. 2008). Different methods have been
developed depending on the nature of the metabolites of
interest. Reversed-phase liquid chromatography (RPLC)–
MS has been used for global proﬁling of metabolites
(Plumb et al. 2006). A RPLC–MS approach is also used for
the proﬁling of lipids, allowing the detection of more than
hundred lipids of various classes (Hu et al. 2009; Laakso-
nen et al. 2006; Verhoeckx et al. 2004). Polar metabolites
are mostly analyzed by hydrophilic interaction chroma-
tography (HILIC–MS) (Bajad et al. 2006; Tolstikov and
Fiehn 2002) or after derivatization before RPLC–MS
(Carlson and Cravatt 2007b).
A disadvantage of LC–MS is ion suppression: ionization
of metabolites may depend on the presence of matrix
compounds, particularly with electrospray ionization (ESI)
and, to a lesser extent, atmospheric pressure chemical
ionization (APCI). This can be overcome to some extent by
miniaturization of electrospray ionization to nanospray
ionization and by a better separation of metabolites.
Obviously, the best quantitative results can be obtained
using isotopically labelled reference metabolites for each
metabolite in a targeted approach, but this cannot be
applied to the proﬁling of a large number of metabolites,
either because the labelled metabolites are not available, or
for cost reasons. Instead, isotope tagging methods can be
developed for targeted metabolite classes (Guo et al. 2007).
To increase the peak capacity in LC, options are smaller
particles in LC columns (requiring often higher pressure of
the LC) (Plumb et al. 2006), using longer columns such as
monolithic columns (Tolstikov et al. 2003). Comprehen-
sive LC9LC approach can also be used (Stoll et al. 2007),
but it is less straightforward compared to GC9GC, as less
options are available for refocusing peaks in the second
dimension. High separation efﬁciency can also be obtained
by CE–MS. However, migration times are often less
reproducible and sensitivity is often lower as compared to
LC–MS. Still, promising applications of CE–MS for
metabolites carrying a charge at a certain pH have been
reported (Soga et al. 2003).
The strategy for identifying metabolites in LC–MS
differs from that used in GC–MS, as only the molecular ion
is most often detected. Additional MS/MS fragmentation
experiments are required to obtain more information about
the structure of the metabolites. However, these MS/MS
spectra depend on the equipment and experimental condi-
tions used, and are usually not as comparable as they are
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MS and especially of Fourier transformed MS (FT-ICR or
Orbitrap) allows the acquisition of metabolite proﬁles with
high mass accuracy, i.e. better than 3 ppm. This allows
often to identify the elemental composition of a metabolite
using internal mass calibration, and with TOF MS data
often the isotopic pattern is taken into account (Kind and
Fiehn 2007). Then in combination with using databases and
possibly MS/MS information, the provisional assignment
of those metabolites present in the database is often pos-
sible. However, it should be mentioned that often several
isomers are possible with the same elemental composition;
and obviously not all metabolites, especially dietary com-
pounds and biotransformed (after ingestion) plant metab-
olites, are present in databases yet. Next, the alignment of a
set of LC–MS chromatograms is in principle more
straightforward if data are acquired with high MS
resolution.
Direct infusion (DI)-nanospray ionization-high resolu-
tion MS can also be used for metabolomics proﬁling
(Boernsen et al. 2005), including for lipids (Han and Gross
2005). The advantage is high throughput of samples. In
recent years the analytical performance of DI-MS has been
improved and several applications in metabolomics have
been published. Extension of the dynamic range was
achieved using wide scan FT-ICR MS method, using col-
lection of multiple adjacent selected ion monitoring win-
dows that are stitched together (Southam et al. 2007). If
proper internal standards are used, linearity up to nearly
three decades can be achieved (Han et al. 2008). However,
for those compounds where no proper correction with
(preferably isotopically labelled) internals standards are
possible, limits in the quantiﬁcation of metabolites are
commonly observed due to possible ion suppression
effects. These can be prevented (at least to some extent)
using more extensive sample preparation. Matrix assisted
laser desorption ionization (MALDI)-MS has also been
used for metabolite proﬁling, however, when applied to
small molecules, it is generally less quantitative compared
to ESI (Wang et al. 2009).
A key aspect in metabolite proﬁling methods with MS is
how to realize comparability of studies and data. Recently,
a set of minimum requirements for reporting chemical
analysis of a metabolite proﬁling experiment has been
suggested (Sumner et al. 2007). However, the minimum
requirements for the validation of metabolite proﬁling
methods have not been described yet, and one often
encounters publications where the validation of an analyt-
ical metabolite proﬁling method is not well described.
Validation should include at least a description of the
calibration model (linearity and range), repeatability and
intermediate precision, accuracy (use of matrix variation
studies, etc.) and lower limit of quantiﬁcation. In addition,
the recovery, reproducibility, robustness (e.g. different
technicians, freeze-thaw cycles, etc.) and carry over should
be characterized. When large series of samples are ana-
lysed, the use of quality control samples is recommended
to control the analytical systems performance, or to com-
pensate for drift of the chromatographic system or the mass
spectrometer (van der Greef et al. 2007). Comparison
between metabolomics studies can be best achieved by
reporting ultimately concentrations of identiﬁed peaks
rather than relative peak areas. In addition, internal stan-
dards added to the sample prior to sample preparation
improves quantiﬁcation accuracy.
Nutritional metabolomics experiments can be conducted
in two manners, (i) a non-targeted proﬁling approach
(using direct infusion MS or LC/GC/CE–MS), where the
obtained data may be only semi-quantitative, or (ii) a more
targeted proﬁling approach aiming at quantitative data by
using more internal standards and reference compounds,
ultimately resulting in absolute concentrations. Often a
non-targeted semi-quantitative proﬁling approach is
applied ﬁrst for hypothesis ﬁnding, and a targeted quanti-
tative approach to zoom into biochemical processes and
mechanisms, and to validate mechanisms of action or
markers. The numbers of metabolites covered by the var-
ious MS analytical methods vary a lot, also depending
whether it is a non-targeted proﬁling or a targeted
approach. When using a GC–MS global proﬁling approach
of plasma, the identity of only about 30–70% of the peaks
detected is commonly assigned. In LC–MS experiments,
much less peaks are generally assigned (Wishart et al.
2008). With targeted proﬁling, often 50–200 metabolites
can be analyzed with one analytical method. When using a
set of complementary methods, e.g. GC–MS and LC–MS,
often about 100–500 metabolites can be analysed in blood
in a targeted approach, and about 600–1000 can be
detected in a ﬁngerprinting mode (Jiye et al. 2005; Lawton
et al. 2008; Shaham et al. 2008; van der Greef et al. 2007).
Clearly coverage of the methods has to be improved to also
include all metabolites of importance in nutrition research,
eventually present at low concentrations and currently not
measured in metabolomics studies so far published. A list
of relevant metabolites for the nutritional research ﬁeld will
be helpful (see Sect. 7) to guide the development of ana-
lytical metabolomics platforms.
4 Extraction of information from mass spectrometry
metabolomics data
Extraction of information from metabolomics data has
always been aproblematic process. This was true in the long
history of comprehensive analysis of biological materials
and still holds today. For example, in the study of medicinal
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approach was daily routine. Back then, the low tech gold
standard was thin layer chromatography (1D or 2D) in the
‘pre’ HPLC, GC, MS and NMR era, because it was cheap,
and provided detailed information about sample composi-
tion (primary and secondary plant metabolites). Metabolites
were visualized by coloring reaction with a multitude of
different spraying reagents and/or ﬂuorescence and the data
was captured by photography and notes in logbooks. Data
extraction was very laborious, inefﬁcient and ineffective.
Progress in analytical technology brought HPLC, GC MS,
LC–MS and NMR to these labs, but also in the early days of
these techniques data was captured on paper recorder rolls,
photographic plates, etc. Only after the computer revolution
in the 80’s digital data systems became commonplace to
capture analytical data. We ﬁnally got digital data, and the
main purpose of the software that came along with analyt-
ical instruments was visualization of data, and computer
aided extraction of data in a manner similar to what was
done in the past with a ruler, pair of scissors and other
utensils.
Currently NMR and MS (LCMS and GCMS) are the
metabolomics workhorses. In the past decade advances in
analytical technology have provided us with reliable
instrumentation capable of producing vast amounts of very
rich data at increasing higher speeds simply because we
need this (that’s what we told the instrument companies).
The resulting data burden is commonly regarded as one of
the major bottlenecks in analytical laboratories, and is not
speciﬁc for metabolomics. The complexity and richness of
metabolomics data (and also mass spec proteomics data)
makes the ‘omics’ community the hardest hit.
Extraction of information from mass spectrometry met-
abolomics data may be done with a diverse set of approa-
ches, methods and tools. The fundamental problem of data
extraction: the same data, extracted with n different meth-
ods, gives n different data sets and probably n different
statistical models (if a single statistical procedure is
applied). In applications where major changes to the me-
tabolome occur (e.g. toxicity models) the differences in the
ﬁnal outcome are relatively small. Unfortunately, in all
other applications where metabolome changes are more
subtle (i.e. nutrition research), data extraction errors have a
dramatic impact on the outcome of a study. For 1D-NMR
popular data extraction methods are binning (total signal in
ﬁxed chemical shift regions of 0.01–0.05 ppm) and peak-
picking (peak ﬁnding, baseline subtraction and alignment)
(Forshed et al. 2005; Vogels et al. 1996). Recently,
deconvolution of NMR spectra into compounds has been
added to these two (Weljie et al. 2006). This approach is
superior from a fundamental, theoretical perspective
because it delivers quantitative metabolite data and not just
NMR signal vectors. It is obvious these three fundamentally
different methods will give different study outcomes when
applied to the same data.
Hyphenated mass spectrometry techniques such as
LC–MS,GC–MS,2D-NMR andinparticularGC9GC–MS,
result in far more complex data than 1D NMR due to the
increased dimensionality. On top of differences between
data extraction methods, all these techniques have a large
numberofoperationandacquisitionmodes,andotherfactors
increasing the data diversity, e.g. for mass spectrometry:
– centroid or proﬁle data acquisition
– ﬁxed scan time (ToF, Q) versus variable scan time (IT)
– positive, negative and alternating/mixed polarity
– full scan MS1 versus SRM in MS
n
– nominal mass resolution to ultra high resolution
– the ability to mix of all of the above
– proprietary data formats and instrument speciﬁc acqui-
sition modes/experiments
All instruments come with software for quantitative data
processing as it is used in routine analysis (e.g. bioanalysis,
residue analysis, environmental analysis, etc.). Unfortu-
nately this software was not made for processing very rich
comprehensive metabolomics LC–MS and GC–MS data
(e.g. 10,000 features in a single ﬁle) of unknown compo-
sition. This software can be used, but this limits the number
of compounds to a few hundred. It should be realized that
multiple target processing with the standard software
results in the best data quality because the process is
supervised and transparent. Integration errors are relatively
easy to detect and correct through well designed and
functional user interfaces. Furthermore, the output does not
contain contaminant peaks, isotopes, (auto)adducts, frag-
ments, multiple charge states etc., in other words it is very
clean data. However, the price of good data quality is time,
in the order of 2–4 weeks (or more), depending on the
number of target metabolites and number of samples. This
data extraction approach has in addition to its time con-
suming nature another more relevant major drawback. It
does not take full advantage of the richness of the data and
the conceptual aspect of metabolomics, the data is
incomplete, information and markers are being lost in the
process. The only solution to this is the use of brute force
comprehensive automated data extraction tools.
Instrument companies have only recently become active
in producing automated data extraction tools for meta-
bolomics and proteomics (e.g. Waters, AB, Thermo, Agi-
lent, Bruker) for selling Plug & Play Metabolomics
Systems. Major disadvantages of these proprietary tools are
(1) they only work for speciﬁc types of data and data
formats and (2) they are black box systems (little is known
about the underlying algorithms). At the same time more
and more 3rd party software is becoming available for
automated data extraction, e.g. GeneData, ACD-Labs,
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programs offer more ﬂexibility with respect to the format
of the input LC–MS data which is a clear advantage when
using instruments from different vendors because data from
the different instruments can be processed in exactly the
same way.
The proteomics and metabolomics communities (and
also others) have been very active the last 15 years in
developing their own tools mainly because commercial
software was (is) not available and/or the poor performance
of some of the available software. Some of these DIY data
extraction tools are freely available on the web (CODA
algorithm (Windig et al. 1996), XCMS (Smith et al. 2006),
OpenMS (Sturm et al. 2008), MZmine 1 and 2 (Katajamaa
et al. 2006), MetAlign (Tolstikov et al. 2003), etc.) and
appear to be cheap solutions to the data extraction prob-
lems. In reality they are not cheap because they all require
training and good understanding of what the software is
doing right and wrong. On top of that issues such as sup-
port and long term continuity are not favorable. For an
excellent overview and description of all these tools and
software see (Katajamaa and Oresic 2007).
The various automated data extraction tools (commer-
cial, public domain and DIY) use different algorithms.
Popular approaches include:
(1) Peak detection and integration, followed by alignment
in the feature space.
(2) Warping of the m/z—retention time plane (alignment
at raw data level), background and blank subtraction,
followed by peak detection and integration.
(3) De-isotoping of data after Steps 1 or 2, e.g. correla-
tion analysis, accurate mass data (de-isotoping may
also be done as a 1st step in data extraction).
(4) Metabolite extraction by using spectrum information:
deconvolution, spectrum libraries, accurate mass, etc.
(5) ….
Analogous to NMR (see above) the extraction of
metabolite information (#4) is strongly preferred compared
to the extraction of all the features in the data: the possi-
bility of getting 15000 features from a single LC–MS ﬁle
seems very impressive, but these represent a much smaller
number of metabolites.
A quick search on the web resulted in approximately 20
different tools for automated data extraction (commercial
and public domain). None of these tools is generic, i.e. they
can only be used for either low or high resolution data,
centroid or proﬁle data, etc. The functionality and perfor-
mance of all these tools is a white spot on the metabolo-
mics map, and it is widely known that all automated data
extraction tools have their speciﬁc problems which result in
data with a variable amount of errors. The fact that high
quality raw data is being corrupted due to these errors is
very alarming. Typical problems include:
– missed peaks
– integrated noise peaks
– database mismatches
– misalignment
– integration errors
These errors become more and more dominant in the
data at low signal to noise ratios. All algorithms eventually
stumble on classiﬁcation problems such as: is this noise or
signal? Is this peak A or B or neither of the two? Are these
spectra the same?, etc. Unfortunately, many metabolites of
interest happen to be present at low concentrations and at
low signal to noise. These extraction errors have major
detrimental effects on the outcome of metabolomics stud-
ies. The majority of these tools, unlike the standard quan-
tiﬁcation tools provided by instrument companies, are
applied without supervision in batch processing mode, and
typically do not have interactive review and error correc-
tion functionalities.
It is obvious that there is big need for improvements in
the area of data extraction. The ultimate goal is a (set of)
perfect tool(s), but it is expected this will take quite some
time. Development of new better algorithms and software
(user interfaces, databases, etc.) are relatively slow pro-
cesses, and a lag between availability of the appropriate
data extraction tools and rapid technological/methodolo-
gical innovation is inevitable. A serious implication of this
lag is that there is no point to waiting for the perfect
solution. It is equally important to focus on workﬂow
optimization and quality control measures to detect, char-
acterize, and reduce data extraction errors for the currently
available metabolomics data extraction tools. International
collaboration, between data extraction software experts and
users, is essential, and would ideally involve programs for
selecting well characterized test data (LC–MS, GC–MS,
etc.) and benchmarking of existing and new data extraction
tools/algorithms. Analysis and sharing of benchmarking
results (the good and the bad) is essential for improving the
data extraction software. This iterative process will even-
tually lead to many, almost ﬂawless, solutions for high
throughput automated data extraction.
5 Multivariate analysis considerations for
metabolomics studies
The multivariate analysis considerations and procedures for
metabolomicsstudiesareroughlycomparabletothoseinthe
microarray ﬁeld (Broadhurst and Kell 2006; D’Haeseleer
2005; Goodacre et al. 2007; Westerhuis et al. 2008).
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multivariate analysis component of any metabolomics study
also impact those in nutritional metabolomic (Broadhurst
and Kell 2006; Garosi et al. 2005). Basic approaches to data
analysis include classiﬁcation, dimensional reduction,
visualization, pattern recognition, and modeling (Broad-
hurst and Kell 2006; Brown et al. 2000; Goodacre et al.
2007; Jansen et al. 2004; Lindon et al. 2001; Tamayo et al.
1999; Trygg and Wold 2002; Wold et al. 2001). This sec-
tion addresses multivariate analysis in the context of the
mathematical (dimensional) reduction of large multivariate
or megavariate (or numerical) data sets, e.g. into smaller
parcels of data that can be comprehended by humans and/or
into models that can predict behavior or classify a sample
into a group of interest (e.g. control, diseased). Bioinfor-
matics issues related to biological interpretation of the data,
e.g. pathway and/or literature annotation and systems biol-
ogy, and issues related to inter-lab data sharing and inte-
gration are discussed in Sect. 7.
Arguably the most important conceptual issue that dis-
tinguishes nutritional metabolomics studies from those in
other areas, such as toxicology, pharmacology or disease
diagnostics (Bhattacharjee et al. 2001; Garber et al. 2001;
Garosi et al. 2005; Kenny et al. 2008; Lindon et al. 2001),
is that the signals may be more subtle, an issue that makes
the speciﬁcs of experimental systems even more demand-
ing. In general, the choice of experimental question is, or
more precisely needs to be, directly and inextricably linked
with the experimental design (Bidaut et al. 2006; Brown
et al. 2000; Jansen et al. 2004; Taylor et al. 2002; Trygg
and Wold 2002; Wold et al. 2001). It is at best extremely
difﬁcult and, often, impossible to rescue a study that is
poorly designed. By building the multivariate analysis in as
part of the experimental design, it is possible to avoid
studies that are doomed from the start and to make sure the
study will be sufﬁciently powerful (statistically speaking)
to draw conclusions, deﬁne models, or make predictions—
all while avoiding over-ﬁtting, the bane of large multi-
variate studies (Broadhurst and Kell 2006; Westerhuis et al.
2008).
One constant trade-off that exempliﬁes the issues related
to experimental/analytical design is between speciﬁcity and
power (e.g. such as occurs when building a model in a
tightly controlled biological model system) versus robust-
ness and generalized applicability (such as occurs when
building a model in a broad human population) (Bhatta-
charjee et al. 2001; Garber et al. 2001; Kristal et al. 2005).
A general study seeking to describe the metabolome
present in a person or animal on one or another given diet,
for example is inherently different from a study geared at
building a proﬁle that can distinguish the individual on
those diets (Shi et al. 2004). This, in turn, differs from one
that seeks to distinguish the effects of these diets in only
one speciﬁc gender or at a speciﬁc age (Paolucci et al.
2004a, b). Similarly, what constitutes a control group
(Bhattacharjee et al. 2001; Garber et al. 2001)? Is someone
who is medicated or someone with a known disease
included (Rozen 2005)? Are they equally represented
(Paolucci et al. 2004a, b)? Are numbers representative of
the general population? This continues as one reﬁnes and
deﬁnes progressively more speciﬁc/narrow criteria (or,
alternatively, progressively broader, more robust criteria).
Another choice is whether one wants to ﬁnd the few most
powerful single markers (Kenny et al. 2008), or whether
one aims at a general proﬁle (Goodacre et al. 1996; Pa-
olucci et al. 2004b). Is the long-term goal clinical or sci-
entiﬁc, a choice that often changes the acceptable options
for model building? Clinical models generally prioritize
robustness, simpliﬁed upstream analysis, and often cost per
analysis and throughput, whereas scientiﬁc models might
prioritize maximum information about a very limited
sample set, and be more willing to accept initially costly
and complicated analytical approaches.
Another closely related issue in terms of matching the
multivariate analysis approach and the experimental design
consists of determining, ideally in advance, what the
quality control metric will be, and how errors will be
viewed (Broadhurst and Kell 2006; Paolucci et al. 2004b;
Rubingh et al. 2006; Tominaga 1999; van den Berg et al.
2006; Wold et al. 2001). In practice, the standard to which
one’s data analysis must be held is often considered—for
better or worse—an extremely subjective one. In some
cases, the chosen metric will be an internal validation, e.g.
examining overﬁt of class assignment by permutation
analysis (Broadhurst and Kell 2006; Paolucci et al. 2004b;
Rubingh et al. 2006; Westerhuis et al. 2008). Alternatively,
the standard might be the same metric, but from a blinded
cohort (Shi et al. 2004). In a descriptive study, it may be
the development of a model that captures class identity
within a cohort, or, alternatively, between two different
cohorts (Shi et al. 2002, 2004). In other cases, it may be
clinical measures such as speciﬁcity, sensitivity, positive
predictive value, or negative predictive values. In some
cases, a measure of distance from one or more classes
might be of interest; in others, a more Bayesian viewpoint
of probabilistic class assignment may be considered more
useful. Finally, reciprocal errors cannot always be consid-
ered equivalent, e.g. the clinical cost of a false positive and
false negative clinical test differ substantially.
A second general concept is that of over-ﬁtting
(Broadhurst and Kell 2006; Rubingh et al. 2006; Wester-
huis et al. 2008). Over-ﬁtting is probably, today, the single
greatest multivariate analysis problem that we observe.
Basically, overﬁtting is the consequence of an incorrect
(over-zealous) use of an multivariate analysis approach to
describe a dataset and/or make predictions (e.g. about
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123classiﬁcation), for example using PLS-DA to ﬁnd metab-
olites that distinguish two classes of interest. The problem
lies in the ability of algorithms such as PLS-DA to ﬁnd
solutions in some spaces where no real solution exists. For
example, PLS-DA can separate two groups comprised
completely of random data (Westerhuis et al. 2008). The
gold standard here is biological replication in a blind, new
dataset (Kenny et al. 2008; Shi et al. 2002, 2004).
The third general concept is that of disclosure. At the
level of the ﬁeld as a whole (or the individual who may
be reading a grant or paper in it), one of the solutions,
indeed arguably the best solution, to this suite of problems
is full disclosure of what is done. The overall goal of the
Metabolomic Standard Initiative (http://msi-workgroups.
sourceforge.net/) is to enable different metabolomics groups
to talk with each other. Within the multivariate analysis
component of the standards initiative the goal is, in part, to
request, and, ideally, eventually demand, sufﬁcient infor-
mation so as to be able to really understand what was done
and catch key problems (Goodacre et al. 2007). Thus we
seek to deﬁne and encourage standardization at the level of
reporting data, not at the level of conducting analysis.
The fourth and ﬁnal general concept that we can now
address is the most powerful way to attack metabolomics
data. This may be broken into at least three pieces. (i) Do
we know, for any question of interest, tools which always
work? To our knowledge, the answer is no. (ii) Do we
know, for any speciﬁc class of metabolomics question (e.g.
modeling nutritional intake, discriminating individuals on
either of two diets), whether there are tools (i.e. algorithms/
multivariate approaches) that always outperform other
tools with respect to a given metric (e.g. accuracy,
robustness, overﬁt characteristics)? In the experience of
one of us (BSK), components based analysis (PCA, PLS,
PLS-DA, etc. (Trygg and Wold 2002; Wold et al. 2001))
always performs as well as or better than pure distance
based algorithms, such as clustering and self-organizing
maps, on metabolomics data (Paolucci et al. 2004a; Shi
et al. 2002, 2004). This comment is very speciﬁc, however,
for a very deﬁned problem—caloric intake in rats. That
said, we have looked at other data sets (non-metabolomics)
where self-organising maps and clustering outperform
projections. Others have had success with machine learning
approaches, support vector machines, etc. (Ellis et al. 2002;
Kenny et al. 2008; Lindon et al. 2001; Tominaga 1999).
Together, even this anecdotal argument suggests that we
are not yet ready to answer this question.
Indeed, while it is conceptually true that we should be
able to match algorithm to question, it appears that we
remain a long way from really being able to assign this
match with conﬁdence [i.e. which method(s) work for
which question(s)]. Not everyone agrees. There are, for
example, those who are convinced genetic algorithms, or
random forest, or PLS-DA answer all questions about
group classiﬁcation, but in reality each has strengths and
weaknesses. In some datasets, all three will essentially
yield equivalent variables as being important and equiva-
lent class assignments. I have also seen the opposite, where
each identiﬁes different variables as important and makes
different class predictions (and all with relatively high
accuracy). Thus, for the moment, we have no robust
answers, only answers that are valid within a deﬁned
experimental lens
6 Metabolite identiﬁcation in mass spectrometry-based
metabolomics
6.1 Current state of the art
Metabolite identiﬁcation is an essential part of any meta-
bolomics experiment. Unfortunately, because metabolite
identiﬁcation is one of the most difﬁcult and time con-
suming steps in metabolomics this crucial process is often
deferred to the ﬁnal stages of many studies and therefore
left largely unﬁnished. In some cases, it is ignored alto-
gether. Without formal compound identiﬁcation, the dis-
covery of any metabolically interesting patterns or clusters
(via PCA or PLS-DA) is largely meaningless.
The challenge of metabolite identiﬁcation, especially for
mass spectrometry, lies in the fact that there are potentially
thousands of compounds that can match a given parent ion
mass or a given atomic composition. The situation is made
even worse given that most metabolomics experiments
generate hundreds or even thousands of different masses.
In the past, compound identiﬁcation via mass spectrometry
required the use of complementary analytical techniques,
such as NMR, IR, or specialized chemical assays. How-
ever, this is now changing. In particular, with the intro-
duction of improved separation technologies, higher
resolution mass spectrometers, smarter ‘‘mass analysis’’
algorithms, more innovative chemical labelling schemes,
more comprehensive MS databases and a better under-
standing of the ‘‘standard’’ metabolic composition of most
organisms, it is now possible to conﬁdently and rapidly
identify many metabolites via MS (Guo et al. 2007; Kind
and Fiehn 2007; Kopka 2006; Tikunov et al. 2005).
Ashasbeenpreviouslydiscussed,MS-basedexperiments
can be done in any number of ways using many different
kinds of separation (GC, LC, CE, 1D, 2D), ionization (EI,
MALDI, ESI, APCI, CI) and detection (parent-ion-only,
parent ion ? EI fragmentation or parent ion ? soft sec-
ondary fragmentation) techniques. Consequently a given
MS-based metabolomics experiment can generate 3 general
types of data or mass spectral tags (MSTs): (1) parent mass
only; (2) parent mass ? chromatographic retention time or
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retention time. These properties, if properly documented,
can allow identiﬁcation of both previously known and
hitherto unidentiﬁed compounds. The identiﬁcation of
unknowns is done by measuring the MSTs of postulated
pure/authentic compounds that may match features of the
unknown MST (Kopka 2006).
This document discusses the needs and requirements
regarding data, databases and software for MS-based
metabolite identiﬁcation. In particular we have attempted
to provide a framework or a series of recommendations
regarding how metabolite identiﬁcation can be facilitated
in an MS-based metabolomics experiment. In doing so we
have used the databases and software models developed for
MS-based proteomics as a template for MS-based
metabolomics.
6.2 MS-based ‘‘pure’’ metabolite databases: current
limitations and recommendations
There are 3 types of MS-based metabolite databases: (1)
those that provide raw, unannotated MS (GC–MS or LC–
MS) spectral data of bioﬂuids or tissue extracts; (2) those
that provide annotated MS (GC–MS or LC–MS) spectral
data or MST’s of bioﬂuids or tissue extracts and 3) those
that provide reference MS spectra or MST’s (GC–MS or
LC–MS) of pure compounds. The ﬁrst two types of dat-
abases represent archival reference data of MS-based
metabolomics experiments. They can be used to facilitate
compound identiﬁcation and are often used in general
metabolomic analysis. However, the most useful databases
for compound identiﬁcation are those in category 3. These
include the NIST GC–MS database, the Metlin database
(Smith et al. 2005), the Golm Metabolome database (Ko-
pka et al. 2005), BinBase (Fiehn et al. 2005), SetupX
(Scholz and Fiehn 2007), the HMDB LC–MS/MS library
(Wishart et al. 2007) and others (Moco et al. 2006). Min-
imally, these kinds of databases should include the name,
chemical formula and monoisotopic mass (to 5 decimal
places) of a signiﬁcant number ([500) of metabolites or
chemically modiﬁed (trimethylsilated) metabolites. Ideally
these databases should also include chromatographic
retention times or retention indices (for both GC and LC
separations) as well as fragment ion mass data (EI or MS/
MS fragmentation). As with similar kinds of proteomics
MS databases, these metabolomics MS databases should be
searchable by (1) elemental composition; (2) parent ion
mass; (3) retention time/index; and/or (4) mass fragment
pattern. A major limitation of LC–MS relative to GC–MS
is the fact that retention times and retention indices for LC
methods are not generally reproducible and therefore
cannot be used as reliably as GC retention indices.
Potentially, the establishment of a ‘‘universal’’ calibration
standard of 5–7 compounds with varying polarity that
could be spiked into LC separations would provide a means
of making LC retention times both meaningful and share-
able. Another particularly useful addition to these kinds of
MS-based metabolite databases would be the possibility of
restricting the search to certain kinds of compounds (i.e.
endogenous metabolites only, known mammalian metab-
olites only, drugs only, toxins only, metabolites speciﬁc to
a certain tissue or bioﬂuid, etc.) or combinations of
metabolite classes. Furthermore these databases should
provide experimental details (images of spectra, collection
conditions, MS spectrometer parameters, collision ener-
gies, instrument type, date of collection, lab/individual who
collected the data) concerning the origin or source of their
pure compound reference spectra. While it would be
preferable if these MS-based metabolomics databases were
freely accessible and freely downloadable (as many MS-
based proteomics databases are), we appreciate the fact that
commercial possibilities exist for the sale and distribution
of these kinds of MS resources. Nevertheless, we would
encourage the community (both academic and industrial) to
do their best to make their database resources publicly
accessible and adherent to these standards.
Because the number of compounds of interest to met-
abolomics researchers easily numbers in the thousands
and because different organisms have profoundly different
metabolomes, it is almost impossible for a single lab or a
single investigator to have access or an interest in col-
lecting referential MS spectra for ALL metabolites.
Therefore, there is a need to establish a process by which
individuals from many different metabolomic interests or
backgrounds may contribute to a common repository of
MS (GC or LC) reference compound spectra. While
several compound reference databases already exist
(NIST, the SDBS) these are general chemical databases
and they are not limited to metabolites or compounds of
biological interest. What is really needed is the equivalent
of a GenBank or PDB for MS spectral deposition. Such a
model allows users to deposit data to a common reposi-
tory so that it can be searched, shared or used by other
scientists. Already the NMR metabolomics community
has started depositing their reference compound spectra
into a common repository, called the BioMagResBank
(Ulrich et al. 2008). We would advocate for the estab-
lishment of a similar entity (lets call it the BioMSBank)
to support submission (and searching) of referential MS
(LC–MS and GC–MS) metabolite spectra. We would
advocate that such a resource store its data in a common
data exchange format such as XML (extensible mark-up
language).
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limitations and recommendations
Currently most MS-based metabolite identiﬁcation soft-
ware is a proprietary stand-alone application tied to a
proprietary MS instrument. This is somewhat contrary to
the trends seen in other ‘‘omics’’ software development.
Indeed, over the past decade, the trend for most ‘‘omics’’
software is towards web-based applications or web-server
delivery. This has numerous advantages (accessibility,
speed, improved maintenance, no need for installation
support) and it is the way in which most MS-based
proteomics software is now available—both commer-
cially and academically. We believe that MS-based
metabolite identiﬁcation software should move to this
model. We also believe that MS-based metabolite iden-
tiﬁcation software should emulate many of the features
used by MS-based proteomics software. This includes
support for database or subdatabase selection, support for
different mass list input formats, support for chemical
modiﬁcation corrections (in this case TMS or dimethy-
lation), and inclusion of additional MST data (retention
index, parent ion mass, fragment ion patterns, etc.).
Obviously this kind of software needs to sit atop an
appropriately maintained database of referential metabo-
lite spectra (see above).
A separate kind of software tool that is unique to meta-
bolomics (and small molecule MS work) is elemental or
chemical formula prediction software. Given sufﬁciently
high mass accuracy (1–2 ppm) and resolution, it is possible
to use the parent ion mass spectrum to determine the ele-
mental composition and, in many cases, the identity or
approximate identity of a compound. Recently Kind and
Fiehn have developed a series of 7 heuristic rules for
chemical formula extraction and compound identiﬁcation
(or ranking) from high resolution MS spectra (Kind and
Fiehn 2007). With the increasing availability of FT-ICR and
Orbitrap MS instruments, there is a distinct possibility that
this approach may offer a powerful adjunct, or even
replacement, to MST-based metabolite identiﬁcation. In
particular, with the growing knowledge about what is found
or ﬁndable in many metabolomes (*1000 metabolites in
microbes, *3000 metabolites in mammals), the use of
chemical formula prediction, followed by rapid scanning
for formula matches to known metabolite lists could prove
to be a very fast, simple and robust method to metabolite
identiﬁcation—especially among organisms that have well
characterized metabolomes. We would advocate that more
effort be devoted to this particular kind of MS-based
metabolite identiﬁcation and that the software be made
available through easily accessible web-server applications.
6.4 Metabolite quantiﬁcation and standards: limitations
and recommendations
While MS-based approaches are widely recognized for their
sensitivity and capacity to identify large ([100s) of
metabolites, they are not generally recognized as being
useful in metabolite quantiﬁcation. This has often been the
Achilles heel to many MS-based approaches. However,
with the recent successes in using isotopic afﬁnity tags
(such as ICAT) to make MS-based proteomics reasonably
quantitative, there is a distinct possibility that similar iso-
tope tagging methods could make MS-based metabolomics
equally quantitative (Carlson and Cravatt 2007a; Guo et al.
2007). We believe that the issue of metabolite quantiﬁcation
should be made a priority in MS labs and that efforts that
focus methodological improvements or software improve-
ments to make rapid and accurate metabolite quantiﬁcation
possible should receive both encouragement and support
from the metabolomics community. Indeed, identiﬁcation
without quantiﬁcation is the bane of many analytical
chemists—as well as many metabolomics researchers.
Recently the proteomics community has pushed for the
establishment of standards to assess the performance of
instruments, methods and labs in identifying and quanti-
fying proteins from deﬁned mixtures. We believe that
similar initiatives should be undertaken in the metabolo-
mics community. The use of deﬁned metabolite mixtures
(speciﬁc to plants, microbes and mammals) would provide
a means to objectively assess the performance and reli-
ability of algorithms, databases and protocols used in MS-
based metabolite identiﬁcation and quantiﬁcation. Indeed,
the use of standardized metabolite mixtures would provide
much-needed validation of existing methods and a means
of objective assessment of emerging methods.
6.5 Metabolite identiﬁcation: consensus
recommendations
(1) Metabolite identiﬁcation (and quantiﬁcation) must be
a priority in any MS-based metabolomics experiment.
(2) Metabolites should be identiﬁed or classiﬁed as
either: (a) unknown; (b) belonging to a certain
chemical class; (c) putatively identiﬁed by a match
to a database MST or (d) conﬁrmed with an authentic
standard.
(3) GC–MS and LC–MS databases should become open
source (using XML), open for public deposition and
much more standardized in terms of the information
they provide.
(4) The use of a standard set of externally spiked-in
retention markers (5–7 compounds) would help
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the utility of LC–MS MSTs.
(5) A set of ‘‘gold standards’’ consisting of synthetic
plasma, urine and cerebrospinal ﬂuid (CSF) should be
used by the metabolomics community to assess
existing protocols, check new protocols and verify
inter or intra-lab reproducibility.
(6) These gold standards would each contain 50 chem-
ically diverse, bioﬂuid-speciﬁc compounds with wide
concentration ranges (pM to mM).
(7) Databases containing detailed physico-chemical infor-
mation of known food components (phytochemicals,
nutrients) and food additives must be established to
facilitatenutritionresearchbyMS-basedmetabolomics.
7 Biological interpretation of metabolomics results
After having identiﬁed and quantiﬁed the relevant metab-
olite changes caused by a nutritional intervention, biolog-
ical conclusions need to be drawn related to the research
hypothesis. As yet, dedicated tools for the biological
interpretation of metabolomics data are scarce. In this
section we discuss the challenges posed by biological
interpretation and present suggestions for improvement.
7.1 Challenges
7.1.1 On the level of study design
Nutrigenomics is the study of molecular relationships
between nutrition and the complexity of molecular pro-
cesses, commonly measured with ‘‘omics’’ techniques,
with the aim to extrapolating how such subtle changes can
affect human health (Afman and Muller 2006; Chavez and
de Chavez 2003;M u ¨ller and Kersten 2003; van Ommen
and Stierum 2002). Metabolomics provides an essential
contribution, as nutrition is almost synonymous with
metabolism. In both study design and interpretation of
metabolomics data, a number of aspects related to the
control of unwanted sources of variability, the time of
sampling and the nature of the samples analysed should be
taken into account. Some sources of variation are relatively
easy to be controlled and recorded, such as analytical
instrument performance, sample storage and processing,
and data-processing. Other sources of variability are much
more of problem and need thorough thoughts when
designing your study. Firstly, inter-individual differences
are usually larger than treatment effect. These inter-indi-
vidual differences are partly explained by some variability
induced by non-controlled conditions in the study. It can be
reduced at the urine level but not in plasma or saliva,
through the use of a standard diet (Walsh et al. 2006).
However, large inter-individual differences remain, some
being age- and gender-dependent (Assfalg et al. 2008;
Lawton et al. 2008), others might be related to diurnal
variability, lifestyle, timing of sampling in relation to eat-
ing habits and ﬂuid intake (especially with regard to urines)
or non-compliance in dietary interventions. Discussions are
ongoing on how to best capture these variations in
describing the study design. The new tools developed by
the European Bioinformatics Institute to capture study
metadata (ISA-TAB, ISA-creator and BioInvestigation
Index: http://www.ebi.ac.uk/net-project/projects.html) are
currently adapted by NuGO to carefully capture and
describe nutritional intervention studies. Also, the use of
standardized diets is a frequent topic of discussion. Stan-
dard run-in (pre-intervention) diets will indeed reduce the
variation in especially the urine metabolome (Walsh et al.
2006). Many food components present in diet are traceable
in plasma and urine, either intact or metabolized and
contribute to this variability (Manach et al. 2009; Mennen
et al. 2008). A series of human studies will still be needed
to characterize this variability and to produce valid rec-
ommendations on how to best limit interferences with diet-
induced physiological adaptations.
Secondly, homeostatic (fasting) metabolomics analysis
may be less informative than metabolomics analysis under
perturbed conditions. Unfortunately, only very few exam-
ples exploiting this concept have been published so far
(Kuhl et al. 2008; Shaham et al. 2008; Wopereis et al.
2009). Thirdly, although our main interest will be in organ-
related processes and biochemistry, these are not readily
available in human studies and we thus need to sufﬁce with
body ﬂuids. Plasma and urine have distinct biological
characteristics. Urine generally reports on exposure and
environmental challenges (Fardet et al. 2008b; Walsh et al.
2006, 2007), while plasma reveals endogenous processes,
including inter-organ communication, energy metabolism,
inﬂammation and disease state (Abdel-Sayed et al. 2008;
Kuhl et al. 2008; Wood et al. 2008).
7.1.2 On a single metabolite level
Do we understand the biological function
of the metabolite in the studied matrix?
This question can be addressed at two levels. The ﬁrst is
its ‘‘intrinsic’’ function. For example, glucose has a primary
biological function as energy source. The second is its rel-
evance related to the matrix. Increased glucose in urine
indicates diabetes, while its increase in plasma is primarily
correlated to the post-prandial state and insulin sensitivity.
Many other metabolites have less known or more complex
functions. Besides, metabolite concentrations in distinct
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compartmentalisation plays a role. For instance, metabolite
concentrations in mitochondria may be very different from
the cytoplasmic concentration. Plasma carnitine is not
straightforwardly related to mitochondrial carnitine con-
centration. Glutathione concentrations are higher in liver
than plasma, and strongly ﬂuctuate in a diurnal rhythm
(Blanco et al. 2007).
Metabolomics needs a knowledge base on metabolite
information in the context of its matrix. Clinical chemistry
databases like Young’s effects online (www.fxol.org) are
valuable. The HMDB database (Wishart et al. 2007) pro-
vides a treasure of information on metabolite properties.
NuGOwiki (www.nugowiki.org) potentially adds to this
knowledge base, as any researcher can add biological
observations related to the metabolite. Other applications
related to plasma metabolite concentration changes appear,
like the HORA suite (Bruschi et al. 2008). At this point, a
large knowledge gap still exists in the translation from
metabolite concentration changes in body ﬂuids to organ
biochemistry and (molecular) physiological interpretation.
Do we understand the relevance of the metabolite’s
changed body ﬂuid concentration?
Can we translate organ processes to body ﬂuid readouts?
Biochemistry text books teach us about the glycolysis as an
intracellular process not to occur in plasma. Yet, GC–MS
metabolomics detects most of the glycolysis and citric acid
cycle metabolites in plasma, indicating that those com-
pounds can be transported through the membrane and may
be a measure of the glycolytic activity in certain tissues. Or
is this due to the way of sampling, i.e. red and white blood
cells lysis? Usually we cannot make a simple comparison
between plasma changes and organ changes. The body
strives to maintain homeostasis, and therefore the organs
need to work hard to keep plasma concentrations between
acceptable boundaries, thereby showing much more
metabolite ﬂuctuation in the organs. For instance, absorbed
glucose triggers release of insulin, resulting in inhibition of
triglyceride hydrolysis in adipose tissue, free fatty acid
esteriﬁcation, decreased gluconeogenesis, decreased pro-
teolysis and many other processes in various organs, all
with their ‘‘imprint’’ on the plasma metabolome (Shaham
et al. 2008). Urine functions as an accumulating waste
basket of exogenous compounds and their metabolites,
while plasma levels of these compounds need to be as low
as possible. Furthermore, time lags can be involved
between organ changes and plasma changes. Therefore,
statistical relationships between various compartments
should be treated with care.
A practical approach in this problem is the use of animal
models to establish the link between organ physiology and
pathology, and body ﬂuid (plasma) metabolome changes.
Especially, transgenic mice models are key in unravelling
speciﬁc mechanisms and combined omics technologies
then provide many indications for both the mechanism and
which metabolites should be measured in plasma (Chen
et al. 2008a; de Vogel-van den Bosch et al. 2008; Hansson
et al. 2005; Kleemann et al. 2007).
7.1.3 On a complex level (metabolic ﬁngerprinting)
Do ﬁngerprints really tell us more than the sum
of the individual components?
Nowadays roughly two different strategies can be dis-
tinguished for metabolite investigations: (1) metabolic
proﬁling and (2) metabolic ﬁngerprinting (Dettmer et al.
2007). They should be clearly distinguished here. Meta-
bolic proﬁling focuses on a group or category of metabo-
lites of interest deﬁned a priori (e.g. fatty acids, oxidized
lipids, nucleosides, etc.) and all these metabolites are pre-
cisely quantiﬁed. Metabolic proﬁling is a targeted way to
study different aspects of metabolism and one should need
the assemblage of a whole suite of quantitative methods to
turn metabolic proﬁling into metabolomics. In general,
speaking in terms of metabolomics people refer to meta-
bolic ﬁngerprinting, where metabolite proﬁles are com-
pared with limited a priori knowledge of the metabolites of
interest. Semi quantitative data are acquired by high
throughput analytical methods (such as LC–MS or
1H
NMR) and (bio)markers (ions or chemical shift signals)
revealed by (difﬁcult) multivariate statistical tools. The
identity of the different signals from the ﬁngerprint can
subsequently be revealed by metabolite identiﬁcation pro-
cedures allowing biological interpretation.
The question ‘‘Do ﬁngerprints really tell us more than
the sum of the individual components’’ will be positively
answered by statistics, but biologists struggle with this
truth. Biologists simply want to understand the relevance of
each individual change, and collate these into pathways,
and processes. Furthermore, biologists also exploit the
results that metabolites, pathways and processes are not
changed, whereas metabolic proﬁling is, due to the statis-
tical selection procedures, only focused on the detection of
changes. However, nutritional interventions will often lead
to complex changes and therefore an individual approach
will seldom be enough to understand the underlying
mechanism. Therefore we need to unravel the biochemical
relationships between the components of a ‘‘proﬁle’’.
Pathway tools like Pathvisio (www.pathvisio.org) and
biological network tools like Metacore (www.genego.com)
and IPA (www.ingenuity.com) provide a ﬁrst attempt to
connect these components but (also given the complex
relationship between body ﬂuids and organ biochemistry
described above) are not (yet) up to the task. These tools
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focussing on intracellular processes, and cannot cope with
the characteristics of plasma and urine ‘‘biochemistry’’.
Matching metabolomics technology to biology
In describing nutrition and health relationships, biolo-
gists often can produce a ‘‘wishlist’’ of metabolites to be
identiﬁed and quantiﬁed. So far, metabolomics has pri-
marily been a technology-driven science: the list of the
metabolites analyzed was determined on the basis of their
physico-chemical properties, and usually it does not com-
pletely match with the biologist’s wishlist. Many times,
biologists moaned at only seeing the same amino acid
changes in NMR ﬁngerprinting strategies. A metabolic
proﬁling technique such as lipidomics provides a more
biologically coherent metabolite set and is a method of ﬁrst
choice in many papers. The inﬂammation-related oxylipids
as separated and quantiﬁed by Newman and Pedersen is a
jewel of a biologically relevant targeted lipidome (New-
man et al. 2007). As the metabolites on those platforms are
more strictly linked to certain biological processes, the
interpretation of the data of such platforms is much easier.
Although NMR and MS spectroscopy can detect all kind
of metabolites, there is no single universal technique today
than can provide estimates of all compounds making the
human metabolome. From a biological point of view
therefore, a comprehensive metabolomics analysis should
be the assemblage of several quantitative methods that
analyze the key metabolites from the biochemical path-
ways or signalling processes that are of interest in your
research question. Nutrition deals with metabolism, oxi-
dation, and inﬂammation as primary processes that main-
tain health or promote disease. The advantage of this semi-
targeted approach is that quantitative data are collected for
well-annotated metabolites allowing the implementation of
databases that can be further mined. In addition, highly
sensitive individual assays to probe important low-abun-
dance metabolites with regulatory functions such as eico-
sanoids, not easily detected in current metabolic
ﬁngerprinting approaches may also be needed.
A major limit of the metabolic ﬁngerprinting strategies
is the limited number of metabolites identiﬁed. Therefore
biological interpretation has to be performed on a small
number of metabolites. It is challenging to get a good
biological interpretation based on only fragments of the
overall picture.
Can we separate the exogenous metabolome from the
endogenous health/disease effects hidden in the
metabolome?
The exogenous metabolome can be deﬁned as all
metabolites directly derived from extrinsic factors such as
diet (nutrients & non-nutrients), drugs, toxics and
metabolites produced by the colonic ﬂora. The endogenous
metabolome are intrinsic metabolites involved in or
resulting from primary and intermediary metabolism
formed under direct cell genome/proteome control (Gibney
et al. 2005; Manach et al. 2009). The consumption of a
particular diet or nutrient will induce changes in the
endogenous metabolome but these effects may be made
blurred by the presence, particularly in urine, of a large
number of exogenous metabolites resulting from the
digestion of food. Furthermore, food is also made of ma-
cronutrients that are transformed into compounds partly
identical to some endogenous metabolites. On the other
hand, these exogenous metabolites can also be useful as
markers of food intake. Different metabolite proﬁles were
observed after consumption of high-meat-, vegetarian-,
Atkins-, or high-ﬁsh diets (Rezzi et al. 2007). In fact, one
of the very few methods to precisely estimate food intake is
through quantiﬁcation of speciﬁc metabolites (Landberg
et al. 2008; Noguchi et al. 2006; Sun et al. 2007a, b), and
this may become a valuable application of metabolomics
(Mennen et al. 2006). Moreover, it will not be simple to
understand the separate effects of age, gender, physical
activity, stress, drugs, region etc. Furthermore, we should
not forget the interactions between gut ﬂora and host
metabolism. The large-bowel microﬂora produces meta-
bolic signals that might overwhelm the true metabolic
signals of nutrients in human bioﬂuids (Dumas et al. 2006;
Goodacre 2007). Consequently, it will be hard to divide the
diet induced changes in the metabolome impacting health
into changes deriving from the food itself.
What extra information can be extracted from time–
course metabolomics proﬁles?
Healthy subjects have a remarkable capacity to maintain
homeostasis, through regulation of metabolism, transport,
and effective defence and repair mechanisms in oxidative
and inﬂammatory stress. In the development of nutritional
related diseases this homeostasis may be deregulated.
Disease progression in early, intermediate and late stage of
development has been shown to have distinct metabolome
proﬁles (Harrigan et al. 2005; Lamers et al. 2005). Pro-
cesses involved in these regulatory activities in late stages
of disease seem to be essentially different from processes
involved in early onset disease. With maturing of the
metabolomics technology, more comprehensive invento-
ries of ‘‘normal’’ concentrations spanning the life stages
and sexes become available (Lawton et al. 2008). To better
understand whether the homeostasis in a patient is dis-
turbed, we should have a good estimate of the ‘‘normal’’
concentrations spanning the life stages and sexes. Such
data adds to the clinical chemistry data available and is
indispensable if we want to surpass the level of ‘‘differ-
ential display proﬁling’’.
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other (published) metabolomics studies?
Currently, it is very difﬁcult to compare metabolomics
results from one study to results from another study for two
reasons. Firstly, many different metabolomics platforms
are in use. Each company or institute has its own favorite
technique and derivatization method. Secondly, metabolite
data are often semi-quantitative and not expressed in
absolute concentrations. For this reason, it is difﬁcult to
compare metabolite concentrations to clinical chemistry
reference ranges, but also to published metabolomics
studies. We therefore advocate that initiatives should be
undertaken in the metabolomics community to make
reporting of metabolites in absolute concentrations possi-
ble, rather than using arbitrary units or x-fold changes (see
also Sect. 6.4).
Linking the metabolome to other measurements
Understanding the metabolic and signalling networks
that regulate health and disease is a principal goal of
nutritional research and of post-genomics research in
general. Although it may seem like increasing complexity,
a breakthrough may be obtained by integrating metabolo-
mics with other phenotypic and possibly genotypic infor-
mation. Metabolomics can be embedded with other sources
of data such as histology, functional tests, gene expression,
(targeted) proteomics etc., and this may help to further
understand the metabolome biology. Metabolomics started
as a technology push, but is now getting part of a more
comprehensive phenotyping. Genotype–phenotype linking
studies are now emerging in the area of transcriptomics
(Chen et al. 2008b; Emilsson et al. 2008; Wang et al.
2007), and this linkage is being explored in large cohort
studies (Tracy 2008). Handling of data and results should
change from technology-focused to study-focussed. Only
after this transposition, multi-study comparison is possible
for cross-validation and meta-analysis based on accurate
phenotypic matching. Standardized formats and mark-up
language development will facilitate this development
(Sansone et al. 2008; Taylor et al. 2008). Databases and
LIMS will thus gradually shift from individual data tech-
nology data handling to study-oriented integration com-
bined evaluation of all relevant results.
7.2 Solutions
As earlier mentioned, nutrition deals with metabolism,
oxidation and inﬂammation as primary processes that
maintain health or promote disease. So, metabolites and
metabolomics need to focus on these processes, primarily
(in case of human studies) in plasma. An integrated bio-
informatics solution that helps to map and visualise
changes in metabolite levels and links to knowledge bases
might be useful. This means: translating metabolite chan-
ges to process changes, translating proﬁles to metabolic
processes and transport (including biochemical informa-
tion), and translating plasma observations to organ
(mechanism) processes. All of this sounds like science
ﬁction but we might want to use this as an umbrella for
integrated toolbox development. So, we propose to federate
efforts in metabolome bioinformatics in a number of ways,
in order to achieve this goal. The toolbox should address
several key problems summarised below.
Analytics: biology driven metabolomics platforms.
Biologists should continue creating wish lists of metabo-
lites that are most relevant in the overarching processes of
metabolism, oxidation and inﬂammation. Metabolomics
platforms need to be further developed, combined and ﬁne-
tuned to cover the most important compounds for these
overarching processes. Subsequently, metabolite data
should be quantitative and expressed in absolute units that
can be used for comparing concentrations with reference
concentration ranges used in clinical chemistry and in
publications.
Study design: focus on intra-individual variation by
including at least two samples per person. To control
biological variation that occurs between the volunteers in a
human intervention study at least two samples are needed
per person: one sample before the start of the intervention
and one sample at the end of the intervention. In this way it
is possible to speciﬁcally identify metabolites that are
changed by the dietary intervention by substracting the
inter-individual variation from the data.
Study design: time–course metabolomics (and ﬂuxo-
mics). Taking into account the time–course of metabolism
should provide a dynamic view of changes in metabolic
pathways. In this way we are able to separate time
effects—representing processes and pathology, i.e. rela-
tively slowly occurring changes from healthy physiology to
a state of pathology—from diet effects—usually in the
range of hours as they reﬂect normal kinetic processes,
representing concentration differences as cause from
change in diets. Linking these data to our biochemical
knowledge will result in understanding the underlying
dynamic processes (ﬂuxomics).
Study design: use of challenge tests. The use of chal-
lenge tests with different time points, like for example the
oral glucose tolerance test (OGTT), facilitates the detection
of subtle differences in metabolomics data (Kuhl et al.
2008; Shaham et al. 2008). This should become a part of
comprehensive nutritional phenotyping (van Ommen et al.
2008b).
Study design: parallel human and mouse intervention
studies. To gain a better understanding of the relation
between body ﬂuid metabolite changes and organ
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to be carried out in parallel to animal model studies to
access the target tissues and link changes in metabolite
concentrations in the plasma to organ physiology.
Bioinformatics: metabo-ontology (MO). In the world of
transcriptomics the Gene Ontology Consortium developed
controlled classiﬁcation (ontologies) that describe gene
products in terms of their associated biological processes,
cellular components and molecular functions. We should
also have that for metabolites. This will then become the
basis for statistical approaches on pathways and process
level: metabolite set enrichment analysis (MSEA).
Bioinformatics: plasma oriented biological networks.
We need to build bioinformatics tools that connect plasma
and organs. So far, all pathways and process visualisation
tools are focused on intracellular processes only. Organ
speciﬁc affected processes have been translated into
plasma speciﬁc metabolite proﬁles. Network biology and
modelling approaches for nutrition and health relationships
(van Ommen et al. 2008a) will become important.
We have started to construct these maps, which allow
visualisation of intracellular changes based on changes
quantiﬁed in plasma, for micronutrient metabolomics. This
is an open source (wiki-based) effort in Wikipathways
(Pico et al. 2008), with export options to major pathway
visualisation tools like GenMAPP and Cytoscape (http://
wikipathways.org/index.php/Portal:Micronutrient).
Bioinformatics: integrated workbench. All data analysis
tools needed for nutritional metabolomics might be uniﬁed
into an integrated workbench. This could be established on
a number of levels:
(1) Use of uniﬁed nomenclature and markup language. In
the case of metabolomics, a series of initiatives are
helpful (the metabolomics standards initiative (San-
sone et al. 2006, 2007; Taylor et al. 2008). Simple
agreements like a uniﬁed coding of metabolites still
need to be agreed on, and the HMDB coding
(connected to a synonym ﬁnder) (Wishart et al.
2007) is for the biologist the obvious choice. This
database contains besides all other metabolite iden-
tiﬁers (KEGG, BioCyc, BIGG, Metlin, Pubchem,
ChEBI, CAS and InChI) and chemical information,
also biological information such as cellular, tissue and
bioﬂuid locations, normal reference ranges, associ-
ated disorders, metabolic enzymes, etc.
(2) Agreement on basic issues in datawarehousing and
(pre)processing, changing from analysis-orientation
to study orientation, allowing metadata and other
parameters to ‘‘travel along’’ with the metabolomics
data (Sansone et al. 2006, 2008).
(3) A uniﬁed statistical and bioinformatics workbench,
following the example of Genepattern (Reich et al.
2006). Genepattern is a software package developed
for transcriptomics data analysis, which provides a
comprehensive environment that can support (i) a
broad community of users at all levels of computa-
tional experience and sophistication, (ii) access to a
repository of analytic and visualization tools and easy
creation of complex analytic methods from them and
(iii) the rapid development and dissemination of new
methods. This will function once points 1) and 2)
have been taken care of. Such a suite will allow
LIMS-independent manoeuvring within and between
datasets, if all are ISA-TAB compliant. Given the
large variety of vendors and analytical application,
this is a must.
(4) A plasma-oriented bioinformatics platform. If indeed
our technological output is a list of plasma metabo-
lites provides a good reference starting point. Appli-
cations like HORA (Bruschi et al. 2008) have
understood this and provide useful connected tools.
The plasma oriented biological networks as men-
tioned above (Pico et al. 2008; van Ommen et al.
2008a) continue this exercise.
(5) A common depository/point of access of all available
tools, knowledge and results. The NuGO metabolo-
mics portal (www.nugo.org/metabolomics) was cre-
ated for this purpose and will only ﬂourish if this
becomes a community effort. Hopefully, the meta-
bolomics community, while still in its infancy, is
ﬂexible enough to properly organize itself on com-
mon grounds for the beneﬁt of all.
8 Conclusions
MS techniques which combine sensitivity and selectivity
appear today as the most appropriate to capture the bulk of
the highly heterogeneous human metabolome. A combi-
nation of several MS techniques combined with different
chromatographic methods will likely be needed to offer the
maximum coverage of the human metabolome. No stan-
dards exist yet for the characterization of the human me-
tabolome (Fiehn et al. 2007). Techniques still evolve
rapidly and standards are needed to allow the sharing and
comparison of data between laboratories or studies. The
main obstacles faced today by nutritionists when trying to
obtain biologically meaningful results from metabolomics
studies have been analysed here and various recommen-
dations have been made (Table 1). They should be col-
lectively addressed in the next years. Indeed the goals of
nutritionists should be shared with analysts, statisticians,
(bio)informaticians and companies developing MS equip-
ments and software. This is precisely one of the raison
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123d’e ˆtre of the European Nutrigenomics Organization
(NuGO, www.nugo.org) to facilitate the sharing of ideas
and the emergence of collaborative projects in the ﬁeld of
nutrition. Exchanges with scientists in other disciplines
such as toxicology, medicine or pharmacology should also
be encouraged. Links between major initiatives for tech-
nical developments, database building, training, etc. should
be strengthened and as much as possible coordinated at the
international level.
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